Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Novo Nordisk and Apollo Clinics announce collaboration to launch Obesity Management Programme in…
The partnership will integrate structured care models, healthcare professional training, patient tools, and awareness initiatives…
FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development: GlobalData
GlobalData notes FDA’s acceptance of VCTE as a surrogate endpoint may reduce reliance on biopsies, ease patient enrolment, and…
Zydus Wellness acquires UK based Comfort Click, forays into the UK & EU markets
Zydus Wellness’ subsidiary Alidac UK acquires UK-based Comfort Click and its subsidiaries in Ireland, US and India for GBP 239…
Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of…
EPICS-III trial met primary and secondary endpoints in evaluating Saroglitazar for Primary Biliary Cholangitis patients with…
Sai Life Sciences completes Phase II expansion of production block PB-11 at Bidar facility
The expansion increases total reactor capacity to ~700 KL, supporting large-scale API and intermediate manufacturing for regulated…
TCS partners with Unilab for cloud-based ERP transformation in the Philippines
TCS to implement SAP S/4HANA on RISE to modernise Unilab’s core systems and strengthen its digital infrastructure
FDA approves Pfizer-BioNTech LP.8.1-adapted monovalent COVID-19 vaccine for high-risk groups
The vaccine is approved for adults aged 65 years and older and individuals aged 5 to 64 years with underlying conditions
Eli Lilly announces Phase 3 ATTAIN-2 trial results for oral GLP-1 agonist orforglipron in obesity…
ATTAIN-2 met primary and key secondary endpoints, with weight loss, A1C reductions, and cardiometabolic improvements at 72 weeks
Dr Reddy’s launches Linaclotide for chronic constipation treatment in India
Dr Reddy’s introduces Colozo, the first guanylate cyclase-C agonist approved in India for adults with chronic idiopathic…
Novartis and BioArctic sign collaboration agreement on BrainTransporter technology for neurological…
Novartis may license drug candidate from collaboration with BioArctic, with potential payments of up to USD 772 million and…